Intravenously administered rituximab induces remission of EBV associated non Hodgkin lymphoma confined to the brain in a patient after allogeneic stem cell transplantation.
Stuhler
G
G
University Hospital Tuebingen, Internal Medicine, Dept. of Hematology and Oncology.
Knop
S
S
Topp
M S
MS
Kröber
S M
SM
Ernemann
U
U
Herrlinger
U
U
Einsele
H
H
Kanz
L
L
Hebart
H
H
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000601:surgery; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000601:surgery; D000069283:Rituximab; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab